Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.35 |
| ▸ | RELA | Q04206 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6685962 | 0.80 | CLK4 (0.64) | ADRB2CLK4ALDH1A1CYP2A6AOC3 | |
| SCHEMBL21959073 | 0.78 | ALDH1A1 (0.43) | ADRB2TRPA1ALDH1A1TSHRCES2 | |
| SCHEMBL3126647 | 0.77 | ADRB2 (0.63) | ADRB2CLK4CYP2A6AOC3NPC1 | |
| SCHEMBL2427481 | 0.77 | ADRB2 (1.00) | ADRB2CLK4CYP2A6AOC3 | |
| SCHEMBL533651 | 0.77 | ADRB2 (0.63) | ADRB2CLK4ALDH1A1TSHRCYP2A6 | |
| SCHEMBL1438427 | 0.77 | ADRB2 (0.63) | ADRB2CLK4ALDH1A1TSHRCYP2A6 | |
| SCHEMBL6270017 | 0.77 | ADRB2 (0.63) | ADRB2CLK4CYP2A6AOC3NPC1 | |
| SCHEMBL6850529 | 0.77 | ADRB2 (0.63) | ADRB2CLK4CYP2A6AOC3NPC1 | |
| SCHEMBL10162103 | 0.77 | ADRB2 (0.63) | ADRB2CLK4ALDH1A1TSHRCYP2A6 | |
| SCHEMBL16625771 | 0.77 | CLK4 (0.61) | ADRB2CLK4ALDH1A1CYP2A6AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661535-A | 7H-pyrrolo [3,2-f ] quinazoline derivatives and anti-infective application thereof | 中国医学科学院药物研究所 | 2025-03-21 | — | — | CN | disclosed |
| CN-119013017-A | Pharmaceutical composition for treating cancer comprising an anticancer agent and a novel compound having an inhibitory activity on prostaglandin E2 receptor | 治纳辅医药科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| WO-2023158221-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | 주식회사 카나프테라퓨틱스 | 2023-08-24 | — | — | WO | disclosed |
| CN-116529238-A | Novel prostaglandin E 2 Compounds with receptor inhibiting activity and uses thereof | 治纳辅医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2011132051-A2 | TRICYCLE COMPOUNDS AS PHOSPHODIESTERASE-10 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-10-27 | — | — | WO | disclosed |
| EP-0665223-A1 | Antitumor agent, novel 3(2H)-pyridazinone derivatives and their preparation | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-08-02 | — | — | EP | disclosed |
| EP-0031796-B1 | 4-HETEROCYCLYL-4'-VINYL-STILBENES | CIBA-GEIGY AG (CH) | 1985-01-23 | — | — | EP | disclosed |
| EP-0020298-B1 | BENZOXAZOLYL STILBENES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS OPTICAL BRIGHTENERS FOR ORGANIC MATERIALS | CIBA-GEIGY AG (CH) | 1983-06-22 | — | — | EP | disclosed |
| US-4366189-A | WHITENERS | CIBA-GEIGY CORPORATION (US) | 1982-12-28 | — | — | US | disclosed |
| US-4297234-A | OPTICAL BRIGHTENERS | CIBA-GEIGY CORPORATION (US) | 1981-10-27 | — | — | US | disclosed |
| EP-0031796-A2 | 4-Heterocyclyl-4'-vinyl-stilbenes | CIBA-GEIGY AG (CH) | 1981-07-08 | — | — | EP | disclosed |
| EP-0020298-A1 | Benzoxazolyl stilbenes, process for their preparation and their use as optical brighteners for organic materials | CIBA-GEIGY AG (CH) | 1980-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | ADRB2 109/4885CLK4 3740/4885TRPA1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.